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Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome: Erratum
In the article that appeared on page 1763 of the October 2011 issue of the Journal of Thoracic Oncology, there were errors in Table 3. The correct table
appears below.
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TABLE 3. Summary of Ongoing Phase 3 Immunotherapy Trials in NSCLC
Identifier Treatment Arms Study Design
Planned
Accrual Primary End Point
Estimated
Completion
NCT00409188 L-BLP25 vs. placebo Randomized phase 3 trial in patients with
unresectable stage III NSCLC
1476 OS 2011
NCT00415818 TG4010 Phase 2b/3 trial in MUC1  NSCLC patients with
normal baseline NK levels
N/A N/A N/A
NCT00480025
(MAGRIT)
MAGE-A3 vs. placebo Phase 3 trial in patients with resected MAGE-
A3 stage IB, II, or IIIA NSCLC randomized 2:1
(vaccine:control)
2270 Disease-free survival 2015
N/A CimaVax EGF vs. placebo Phase 3 trial in patients with advanced stage (IIIB/IV)
NSCLC randomized 2:1 (vaccine:control)
579 Survival evaluated in two-
patient strata: aged 60
yr (n  381) and
aged 60 yr (n  198)
N/A
NCT00676507 Belagenpumatucel-L vs.
placebo
Randomized phase 3 trial in patients with stage
III/IV NSCLC as maintenance following first-
line chemotherapy/chemoradiotherapy
700 OS 2011
NCT01285609 Ipilimumab  pax/carbo
vs. pax/carbo
Randomized phase 3 trial in patients with stage IV
or recurrent NSCLC with squamous cell
histology
N/A OS N/A
NCT00707304
(FORTIS-M)
Talactoferrin alfa vs.
placebo
Randomized phase 3 trial in patients with stage
IIIB/IV NSCLC who had failed 2 prior
systemic anticancer regimens for advanced
disease
720 OS 2011
NCT00706862
(FORTIS-C)
Talactoferrin alfa vs.
placebo each in
combination with first-
line pax/carbo
Randomized phase 3 trial in patients with
advanced NSCLC
1100 OS and PFS 2013
EGF, epidermal growth factor; MAGRIT, MAGE-A3 as Adjuvant Non-Small Cell Lung Cancer Immunotherapy; MUC1, mucin 1; N/A, not available; NK, natural killer;
NSCLC, non-small cell lung cancer; OS, overall survival; pax/carbo, paclitaxel/carboplatin; PFS, progression-free survival.
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